摘要
癌症作为一种遗传性疾病是全世界死亡的主要原因之一。传统抗癌选项如化疗和/或放射疗法都有自己的缺点,目前在大多数情况下不能提供治愈。迫切需要拥有更少的副作用更有效的治疗策略。寡核苷酸适配子,也称为化学抗体,是单股DNA或RNA分子,可以绑定到目标分子具有高亲和力和特异性。这样的特异性结合位点绑定寡核苷酸适配子的能力促进外源核酸的传递和与病基因的互动。因此,除了经典的治疗方案,适配子指导的基因治疗已成为一个有前途的抗癌策略。寡核苷酸适配子可以直接提供抗癌核酸,如小干扰RNA、微RNA、antimicroRNA和小发夹RNA、癌细胞或作为靶向配体来指导纳米粒子核酸治疗。本文综述近年来在适配子指导的基因疗法治疗肝细胞癌和其他类型的癌症,揭示这一新型的潜在癌症靶向基因治疗的方法。
关键词: 适配体,基因治疗,微小核糖核酸,核糖核酸干扰,癌症,肝癌
Current Gene Therapy
Title:Aptamer-Mediated Cancer Gene Therapy
Volume: 15 Issue: 2
Author(s): Dongxi Xiang, Sarah Shigdar, Greg Qiao, Shu-Feng Zhou, Yong Li, Ming Q. Wei, Liang Qiao, Hadi Al. Shamaileh, Yimin Zhu and Conglong Zheng, Chunwen Pu and Wei Duan
Affiliation:
关键词: 适配体,基因治疗,微小核糖核酸,核糖核酸干扰,癌症,肝癌
摘要: Cancer as a genetic disorder is one of the leading causes of death worldwide. Conventional anticancer options such as chemo- and/or radio-therapy have their own drawbacks and could not provide a cure in most cases at present. More effective therapeutic strategies with less side effects are urgently needed. Aptamers, also known as chemical antibodies, are single strand DNA or RNA molecules that can bind to their target molecules with high affinity and specificity. Such site-specific binding ability of aptamers facilitates the delivery and interaction of exogenous nucleic acids with diseased genes. Thus, aptamer-guided gene therapy has emerged as a promising anticancer strategy in addition to the classic treatment regimen. Aptamers can directly deliver anti-cancer nucleic acids, e.g. small interfering RNA, micro RNA, antimicroRNA and small hairpin RNA, to cancer cells or function as a targeting ligand to guide nanoparticles containing therapeutic nucleic acids. This review focuses on recent progress in aptamer-mediated gene therapy for the treatment of hepatocellular carcinoma and other types of cancers, shedding light on the potential of this novel approach of targeted cancer gene therapy.
Export Options
About this article
Cite this article as:
Dongxi Xiang, Sarah Shigdar, Greg Qiao, Shu-Feng Zhou, Yong Li, Ming Q. Wei, Liang Qiao, Hadi Al. Shamaileh, Yimin Zhu and Conglong Zheng, Chunwen Pu and Wei Duan , Aptamer-Mediated Cancer Gene Therapy, Current Gene Therapy 2015; 15 (2) . https://dx.doi.org/10.2174/1566523214666141224095105
DOI https://dx.doi.org/10.2174/1566523214666141224095105 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NAFLD: Diagnostic Algorithms for Regulating Patient Fluxes
Current Pharmaceutical Design Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents
Mini-Reviews in Medicinal Chemistry The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry The Prevalence of Hepatitis C Virus Among Blood Donors Attending Samarra's General Hospital
Infectious Disorders - Drug Targets Induction of Apoptosis by Nano-Synthesized Complexes of H2L and its Cu(II) Complex in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Deep Neck Infections: Decisional Algorithm for Patients with Multiple Spaces Involvement
Reviews on Recent Clinical Trials MiR-492 as an Important Biomarker for Early Diagnosis and Targeted Treatment in Different Cancers
Current Cancer Therapy Reviews Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial
Current Pharmaceutical Design Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design Spacer Length: A Determining Factor in the Design of Galactosyl Ligands for Hepatoma Cell-Specific Liposomal Gene Delivery
Current Drug Delivery Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study
Current Radiopharmaceuticals Graphical Abstracts:
Current Radiopharmaceuticals The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets Protein kinases and the Hypoxia-Inducible Factor-1, two switches in angiogenesis
Current Pharmaceutical Design Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology